Trial Profile
An observational study assessing the efficacy and toxicity of eribulin mesylate in French population with metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2014
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2014 New trial record
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.